These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 18473971)

  • 21. Nelarabine.
    Gandhi V; Keating MJ; Bate G; Kirkpatrick P
    Nat Rev Drug Discov; 2006 Jan; 5(1):17-8. PubMed ID: 16485343
    [No Abstract]   [Full Text] [Related]  

  • 22. Nelarabine: a nucleoside analog with efficacy in T-cell and other leukemias.
    Kisor DF
    Ann Pharmacother; 2005 Jun; 39(6):1056-63. PubMed ID: 15870141
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation.
    Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D
    Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new high-performance liquid chromatography method determines low production of 9-beta-D-arabinofuranosylguanine triphosphate, an active metabolite of nelarabine, in adult T-cell leukemia cells.
    Yamauchi T; Nishi R; Kitazumi K; Nakano T; Ueda T
    Oncol Rep; 2010 Feb; 23(2):499-504. PubMed ID: 20043113
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nelarabine (Arranon) for T-cell acute lymphoblastic leukemia.
    Med Lett Drugs Ther; 2006 Feb; 48(1228):14-5. PubMed ID: 16467734
    [No Abstract]   [Full Text] [Related]  

  • 26. Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma.
    Abaza Y; M Kantarjian H; Faderl S; Jabbour E; Jain N; Thomas D; Kadia T; Borthakur G; D Khoury J; Burger J; Wierda W; O'Brien S; Konopleva M; Ferrajoli A; Kebriaei P; Dabaja B; Kornblau S; Alvarado Y; Daver N; Pemmaraju N; Bose P; Thompson P; Al Azzawi H; Kelly M; Garris R; Jain P; Garcia-Manero G; Cortes J; Ravandi F
    Am J Hematol; 2018 Jan; 93(1):91-99. PubMed ID: 29047158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed.
    Prescrire Int; 2009 Feb; 18(99):3-5. PubMed ID: 19382393
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I trial of nelarabine in indolent leukemias.
    Gandhi V; Tam C; O'Brien S; Jewell RC; Rodriguez CO; Lerner S; Plunkett W; Keating MJ
    J Clin Oncol; 2008 Mar; 26(7):1098-105. PubMed ID: 18309944
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway.
    Lonetti A; Cappellini A; Bertaina A; Locatelli F; Pession A; Buontempo F; Evangelisti C; Evangelisti C; Orsini E; Zambonin L; Neri LM; Martelli AM; Chiarini F
    J Hematol Oncol; 2016 Oct; 9(1):114. PubMed ID: 27776559
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
    Lech-Maranda E; Korycka A; Robak T
    Mini Rev Med Chem; 2009 Jun; 9(7):805-12. PubMed ID: 19519505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nelarabine use in leukemias.
    Kisor DF
    Drugs Today (Barc); 2006 Jul; 42(7):455-65. PubMed ID: 16894400
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nelarabine, etoposide, and cyclophosphamide in relapsed pediatric T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma (study T2008-002 NECTAR).
    Whitlock JA; Malvar J; Dalla-Pozza L; Goldberg JM; Silverman LB; Ziegler DS; Attarbaschi A; Brown PA; Gardner RA; Gaynon PS; Hutchinson R; Huynh VT; Jeha S; Marcus L; Messinger Y; Schultz KR; Cassar J; Locatelli F; Zwaan CM; Wood BL; Sposto R; Gore L
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29901. PubMed ID: 35989458
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy of low dose clofarabine in refractory precursor T- acute lymphoblastic leukemia.
    Choi J; Foss F
    Yale J Biol Med; 2006 Dec; 79(3-4):169-72. PubMed ID: 17940627
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FLEND (nelarabine, fludarabine, and etoposide) for relapsed T-cell acute lymphoblastic leukemia in children: a report from Japan Children's Cancer Group.
    Kumamoto T; Goto H; Ogawa C; Hori T; Deguchi T; Araki T; Saito AM; Manabe A; Horibe K; Toyoda H
    Int J Hematol; 2020 Nov; 112(5):720-724. PubMed ID: 32761462
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacologic purging of malignant T cells from human bone marrow using 9-beta-D-arabinofuranosylguanine.
    Hebert ME; Greenberg ML; Chaffee S; Gravatt L; Hershfield MS; Elion GB; Kurtzberg J
    Transplantation; 1991 Oct; 52(4):634-40. PubMed ID: 1926342
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Profile of nelarabine: use in the treatment of T-cell acute lymphoblastic leukemia.
    Reilly KM; Kisor DF
    Onco Targets Ther; 2009 Feb; 2():219-28. PubMed ID: 20616909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clofarabine in pediatric acute leukemia: current findings and issues.
    Hijiya N; Barry E; Arceci RJ
    Pediatr Blood Cancer; 2012 Sep; 59(3):417-22. PubMed ID: 22354543
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study.
    Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G
    Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Drug resistance to nelarabine in leukemia cell lines might be caused by reduced expression of deoxycytidine kinase through epigenetic mechanisms.
    Yoshida K; Fujita A; Narazaki H; Asano T; Itoh Y
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):83-91. PubMed ID: 34825941
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SAMHD1 is a key regulator of the lineage-specific response of acute lymphoblastic leukaemias to nelarabine.
    Rothenburger T; McLaughlin KM; Herold T; Schneider C; Oellerich T; Rothweiler F; Feber A; Fenton TR; Wass MN; Keppler OT; Michaelis M; Cinatl J
    Commun Biol; 2020 Jun; 3(1):324. PubMed ID: 32581304
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.